InfuSystem (INFU) Competitors $8.97 +0.04 (+0.45%) (As of 05:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INFU vs. IRMD, OFIX, CATX, KIDS, SRDX, SIBN, TMCI, TCMD, CVRX, and RCELShould you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include Iradimed (IRMD), Orthofix Medical (OFIX), Perspective Therapeutics (CATX), OrthoPediatrics (KIDS), Surmodics (SRDX), SI-BONE (SIBN), Treace Medical Concepts (TMCI), Tactile Systems Technology (TCMD), CVRx (CVRX), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry. InfuSystem vs. Iradimed Orthofix Medical Perspective Therapeutics OrthoPediatrics Surmodics SI-BONE Treace Medical Concepts Tactile Systems Technology CVRx AVITA Medical Iradimed (NASDAQ:IRMD) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, community ranking, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the media prefer IRMD or INFU? In the previous week, InfuSystem had 9 more articles in the media than Iradimed. MarketBeat recorded 11 mentions for InfuSystem and 2 mentions for Iradimed. Iradimed's average media sentiment score of 0.89 beat InfuSystem's score of 0.02 indicating that Iradimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iradimed 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in IRMD or INFU? 92.3% of Iradimed shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 37.1% of Iradimed shares are held by insiders. Comparatively, 10.2% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, IRMD or INFU? Iradimed has higher earnings, but lower revenue than InfuSystem. Iradimed is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIradimed$71.31M9.76$17.19M$1.4637.63InfuSystem$125.79M1.54$870K$0.06151.69 Which has more risk and volatility, IRMD or INFU? Iradimed has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Does the MarketBeat Community prefer IRMD or INFU? Iradimed received 246 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 64.78% of users gave Iradimed an outperform vote. CompanyUnderperformOutperformIradimedOutperform Votes25264.78% Underperform Votes13735.22% InfuSystemOutperform Votes6100.00% Underperform VotesNo Votes Do analysts recommend IRMD or INFU? Iradimed currently has a consensus target price of $60.00, indicating a potential upside of 9.21%. InfuSystem has a consensus target price of $13.00, indicating a potential upside of 42.86%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Iradimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iradimed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00 Is IRMD or INFU more profitable? Iradimed has a net margin of 26.12% compared to InfuSystem's net margin of 1.12%. Iradimed's return on equity of 23.99% beat InfuSystem's return on equity.Company Net Margins Return on Equity Return on Assets Iradimed26.12% 23.99% 20.45% InfuSystem 1.12%2.78%1.41% SummaryIradimed beats InfuSystem on 11 of the 19 factors compared between the two stocks. Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get InfuSystem News Delivered to You Automatically Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INFU vs. The Competition Export to ExcelMetricInfuSystemSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$193.47M$4.61B$5.18B$19.90BDividend YieldN/A39.52%4.98%3.50%P/E Ratio151.6925.03135.1244.87Price / Sales1.5460.921,248.6418.40Price / Cash14.9252.4438.8921.68Price / Book3.495.576.304.65Net Income$870,000.00$13.58M$118.33M$982.08M7 Day Performance23.98%-1.20%-1.54%-0.80%1 Month Performance33.43%6.17%2.98%1.67%1 Year PerformanceN/A54.99%36.39%25.92% InfuSystem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INFUInfuSystem2.3349 of 5 stars$8.97+0.4%$13.00+44.9%N/A$190.70M$125.79M149.52499Analyst RevisionIRMDIradimed4.4469 of 5 stars$54.94-0.9%N/A+33.1%$696.26M$71.31M37.63110OFIXOrthofix Medical2.0749 of 5 stars$18.10-2.9%N/A+92.4%$690.88M$746.64M-5.781,634Gap UpCATXPerspective Therapeutics2.9792 of 5 stars$9.17-7.7%N/AN/A$618.33M$1.43M0.00116KIDSOrthoPediatrics4.2827 of 5 stars$23.62-2.6%N/A-6.9%$571.98M$189.67M-19.20200SRDXSurmodics4.3502 of 5 stars$38.23+0.2%N/A+18.0%$545.54M$126.08M-47.20376Analyst RevisionPositive NewsSIBNSI-BONE4.3426 of 5 stars$12.91-1.8%N/A-17.6%$538.27M$150.71M-14.03350Analyst ForecastNews CoverageTMCITreace Medical Concepts1.2079 of 5 stars$7.71-2.7%N/A+31.3%$480.33M$187.12M-7.79250TCMDTactile Systems Technology3.9314 of 5 stars$15.94-1.7%N/A+50.9%$382.51M$285.05M24.52980CVRXCVRx3.0934 of 5 stars$14.15-0.4%N/A-20.3%$343.28M$39.29M-5.24200Positive NewsRCELAVITA Medical1.9525 of 5 stars$13.05+1.4%N/A+3.0%$342.17M$50.14M-5.85130Earnings ReportGap Down Related Companies and Tools Related Companies IRMD Competitors OFIX Competitors CATX Competitors KIDS Competitors SRDX Competitors SIBN Competitors TMCI Competitors TCMD Competitors CVRX Competitors RCEL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:INFU) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you wa...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InfuSystem Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InfuSystem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
